Rheumnow Podcast
ACR24 - Day2b
Nov 18, 2024
Joining the discussion are Peter Nash, an expert on JAK inhibitors, Mrinalini Dey, a rheumatologist focusing on methotrexate side effects, and Chris Wincup, who dives into neuropsychiatric lupus. They reveal fascinating insights into JAK inhibitors, their safety, and the importance of vaccinations. Dey shifts perspectives on methotrexate side effects, while she and Wincup emphasize recognizing neuropsychiatric symptoms in lupus, advocating for improved communication and awareness in patient care.
52:27
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- JAK inhibitors can adversely affect immune response to vaccination, particularly delaying effective responses to herpes zoster vaccinations like Shingrix.
- Incorporating palliative care into rheumatology is essential for improving patient quality of life, though referral practices remain inconsistent among clinicians.
Deep dives
JAK Inhibitors and Herpes Zoster Vaccination
JAK inhibitors have been shown to blunt the immune response to herpes zoster vaccination, specifically the Shingrix vaccine. A study highlighted that patients who were on JAK inhibitors had lower antibody levels and suppressed T-cell responses after vaccination, which emphasizes the need for vaccine administration prior to starting JAK therapy. Additionally, interrupting JAK treatment for a short period before vaccination does not significantly improve the response, suggesting that vaccination timing is crucial. This information points to the importance of proactive vaccination strategies in patients who will be receiving JAK inhibitors.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
